Lingohr Asset Management GmbH Has $5.34 Million Stock Position in Medtronic PLC $MDT

Lingohr Asset Management GmbH increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 456.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 56,075 shares of the medical technology company’s stock after buying an additional 46,000 shares during the quarter. Lingohr Asset Management GmbH’s holdings in Medtronic were worth $5,341,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Norges Bank acquired a new position in shares of Medtronic in the 2nd quarter valued at approximately $1,432,698,000. Vanguard Group Inc. lifted its stake in Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after buying an additional 1,895,165 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Medtronic by 332.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock valued at $130,300,000 after buying an additional 1,148,803 shares during the period. Laurel Wealth Advisors LLC increased its position in shares of Medtronic by 8,779.8% during the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock worth $93,243,000 after acquiring an additional 1,057,618 shares in the last quarter. Finally, Altrinsic Global Advisors LLC increased its position in shares of Medtronic by 47.7% during the second quarter. Altrinsic Global Advisors LLC now owns 2,688,334 shares of the medical technology company’s stock worth $234,342,000 after acquiring an additional 868,256 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MDT. CICC Research initiated coverage on shares of Medtronic in a report on Friday. They set an “outperform” rating on the stock. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Daiwa Capital Markets upped their price objective on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Stifel Nicolaus boosted their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Stock Performance

Shares of NYSE MDT opened at $102.96 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock has a 50 day moving average price of $99.60 and a 200 day moving average price of $95.64. The stock has a market capitalization of $131.99 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.66 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).